Systemic-to-pulmonary artery pressure ratio as a predictor of patient outcome following liver transplantation

Table 3 Vasopressor use

	Group 1	Group 2	P-value
Vasopressor use frequency	MAP/mPAP increase during anhepatic period (n = 66)	MAP/mPAP no change or decrease during anhepatic period (n = 25)
No vasopressor use	14	5	0.624
Low dose vasopressor use	39	12	0.341
High dose vasopressor use	13	8	0.214

Following medications are intraoperatively available: Norepinephrine (NE), Epinephrine (EPI), Vasopressin (V), Dopamine or Phenylephrine (PHE). Based on intraoperative documentation at 15 min before reperfusion (anhepatic measurement of MAP/mPAP ratio). The patients were sorted into three different categories: No vasoactive medication use; low dose vasoactive medication use (NE < 0.05 mcg/kg per minute or EPI < 0.03 mcg/kg per minute or V < 0.03 units/min or PHE < 0.1 μg/kg per minute) and high dose vasoactive medication use (NE ≥ 0.05 μg/kg per minute, EPI ≥ 0.03 μg/kg per minute, V ≥ 0.03 units/min or any vasopressor combination). Data are shown as patient number receiving vasopressor therapy at the anhepatic measurement point (15 min before reperfusion). P value was obtained using χ² test. A P-value for < 0.05 was set for statistical significance. MAP/mPAP: Mean systemic-to-pulmonary artery pressure.